Author

Xiaofang Si

Capital Medical UniversityORCID 0009-0000-5076-1201Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:cell signaling & trafficking· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Organism:mouse· 1

Frequent Co-Authors

Xueying MaiiD· 2 shared Yu ZhangiD· 2 shared Hong H. YuiD· 1 shared Wenjing LiuiD· 1 shared Wenjing LiuiD· 1 shared Yu HongiD· 1 shared

Activity by Year

2023-2025 · peak 1/yr

Co-Author Collaboration Network

6 top collaborators · 11 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Xueying MaiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologybioRxivAug 20, 2025

Ex vivo and in vivo CRISPR/Cas9 screenings identify the roles of protein N-glycosylation in regulating T-cell activation and functions

Yu Hong, Xiaofang Si, Wenjing Liu…·Yu Zhang

The paper identifies B4GALT1 as a regulator of CD8+ T-cell function through N-glycosylation, showing its potential as a target for immunotherapy.

DOI 10.7554/elife.108724

𝕏 PostBluesky

ImmunologybioRxivPreprintDec 19, 2023

Lactose and its derivatives are a new class of immune checkpoint inhibitors for cancer therapy

Hong H. Yu, Xiaofang Si, Wenjing Liu…·Yu Zhang

This study identifies lactose and its derivatives as immune checkpoint inhibitors by enhancing CD8+ T-cell function through modulation of galactosylation and Gal-1 interactions.

1 citation

humanproteomics

𝕏 PostBluesky